KRAS and neoplasm: A pre-clinical study performed on a KRAS mutant non-small-cell lung cancer (NSCLC) xenograft model receiving NBF-006 showed that NBF-006 was well tolerated by the animal models; 70–80% of the administered dose was internalized by the tumor tissues, causing significant tumor suppression and prolonged survival [59].